ETON Stock Overview
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ETON from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Eton Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.60 |
| 52 Week High | US$21.48 |
| 52 Week Low | US$3.18 |
| Beta | 1.23 |
| 1 Month Change | 36.68% |
| 3 Month Change | 31.99% |
| 1 Year Change | 445.96% |
| 3 Year Change | 512.50% |
| 5 Year Change | 305.80% |
| Change since IPO | 213.60% |
Recent News & Updates
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
May 21
Increlex And Galzin Acquisitions Will Broaden Treatment Options
Strategic acquisitions and product launches are expected to drive significant revenue growth and expand market reach in pediatrics and rare diseases.Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
May 16
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%
May 02Recent updates
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
May 21Increlex And Galzin Acquisitions Will Broaden Treatment Options
Strategic acquisitions and product launches are expected to drive significant revenue growth and expand market reach in pediatrics and rare diseases.Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
May 16Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%
May 02Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors
Feb 07Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%
Nov 14Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
Oct 07After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
Sep 10Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Shareholder Returns
| ETON | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 14.8% | 1.8% | 0.5% |
| 1Y | 446.0% | -10.1% | 11.1% |
Return vs Industry: ETON exceeded the US Pharmaceuticals industry which returned -9.5% over the past year.
Return vs Market: ETON exceeded the US Market which returned 11.7% over the past year.
Price Volatility
| ETON volatility | |
|---|---|
| ETON Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 11.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ETON has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ETON's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 31 | Sean Brynjelsen | www.etonpharma.com |
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.
Eton Pharmaceuticals, Inc. Fundamentals Summary
| ETON fundamental statistics | |
|---|---|
| Market cap | US$524.82m |
| Earnings (TTM) | -US$4.58m |
| Revenue (TTM) | US$48.33m |
Is ETON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETON income statement (TTM) | |
|---|---|
| Revenue | US$48.33m |
| Cost of Revenue | US$20.06m |
| Gross Profit | US$28.27m |
| Other Expenses | US$32.85m |
| Earnings | -US$4.58m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 58.49% |
| Net Profit Margin | -9.49% |
| Debt/Equity Ratio | 122.7% |
How did ETON perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 08:40 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eton Pharmaceuticals, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |